AI assistant
Nicox S.A. — Capital/Financing Update 2021
Jul 6, 2021
1556_iss_2021-07-06_090920a4-3bfb-491e-b9be-84495f30abbb.pdf
Capital/Financing Update
Open in viewerOpens in your device viewer
Press Release
Nicox: Half-year liquidity contract statement with Kepler Cheuvreux
July 6, 2021 – release at 7:30 am CET Sophia Antipolis, France
Under the liquidity contract entered into between NICOX and Kepler Cheuvreux, the following resources appeared on the liquidity account on June 30th 2021:
- 218,919 shares
- € 128,032.29
- Number of executions on buy side on semester: 1,594
- Number of executions on sell side on semester: 1,298
- Traded volume on buy side on semester: 978,682 shares for € 4,245,529.01
- Traded volume on sell side on semester: 906,908 shares for € 3,977,929.37
As a reminder :
• the following resources appeared on the last half year statement on 31 December 2020 on the liquidity account:
- 147,145 shares
- € 395,631.93
- Number of executions on buy side on semester: 829
- Number of executions on sell side on semester: 609
- Traded volume on buy side on semester: 457,955 shares for € 1,916,480.01
- Traded volume on sell side on semester: 310,810 shares for € 1,312,111.94
- the following resources appeared on the liquidity account when the activity started:
- 0 shares
- € 500,000.00
The liquidity agreement complies with AMF Decision n° 2018-01 dated 2nd July 2018, introducing liquidity agreements on equity securities as permitted market practice.
| Number of Number of Traded volume Number of Number of Traded volume executions in EUR in EUR shares executions shares Total 1,594 4.245,529.01 978,682 1.298 906,908 7 3.400 04/01/2021 15,629 20 67,673.57 16 11,200 25 05/01/2021 8,621 37,156.51 06/01/2021 1 2,000 8,720.00 21 12,400 07/01/2021 14 9,750 42.217.50 9 7,800 08/01/2021 4 3,000 9 9,705 13,200.00 23 11/01/2021 13 9,401 41,834.45 16,295 3 24 12/01/2021 16,064 1.999 8,915.54 39 13/01/2021 16,200 ٠ 2 545 14/01/2021 20 16,270 75,818.20 12 11,455 8 15/01/2021 6,716 31.027.92 18/01/2021 5 5.120 23,910.40 33 28.000 3 19/01/2021 30 18.000 5.400 89,280.00 7 20/01/2021 10 6,301 31,252.96 5.000 3 21/01/2021 38 25,000 122,250.00 2.000 8 22/01/2021 35 20,000 94,000.00 6,000 23 25/01/2021 12,341 56.398.37 $\overline{a}$ 6 9.464 6 26/01/2021 3.059 13,765.50 6 5.400 27/01/2021 28 14,130 63.443.70 28/01/2021 15,000 27 15,520 68.443.20 16 29/01/2021 24 10,000 43,800.00 01/02/2021 31 30,000 02/02/2021 10 19 10,000 7,000 31,500.00 03/02/2021 35 22,000 - 8 9,900 04/02/2021 17 8,773 40,092.61 16 12,000 05/02/2021 19 16,227 73,995.12 23 4 08/02/2021 22,000 99,220.00 2,000 09/02/2021 22 4 12,000 54,000.00 2,000 2 10/02/2021 799 8 3,595.50 4,001 11/02/2021 12 12,000 54,120.00 7 4,777 12/02/2021 33 13,500 60.345.00 4 15/02/2021 4,000 47 23.322 18,240.00 8 8,000 8 16/02/2021 6,000 27,420.00 17/02/2021 11 12,000 54.840.00 ٠ 15 18/02/2021 6,000 27,180.00 ٠ $\overline{\phantom{a}}$ 19/02/2021 7 3,500 4 15,680.00 4,000 22/02/2021 13 10 11,000 49,940.00 6,328 32 23/02/2021 104,274.00 24 19,672 23,172 2 24/02/2021 8 2,001 8,984.49 4,980 2 3,020 25/02/2021 10 7.018 31,721.36 26/02/2021 32 14,881 66,071.64 - 5 01/03/2021 4,001 17,884.47 16 15,000 02/03/2021 17 9,999 44,495.55 |
Sell Side | |||
|---|---|---|---|---|
| 3,977,929.37 | ||||
| 15.028.00 | ||||
| 48,944.00 | ||||
| 54,808.00 | ||||
| 34,164.00 | ||||
| 42,993.15 | ||||
| 73,001.60 | ||||
| 72,609.28 | ||||
| 75,006.00 | ||||
| 2,594.20 | ||||
| 54,182.15 | ||||
| 134,680.00 | ||||
| 27.432.00 | ||||
| 25,400.00 | ||||
| 10,160.00 | ||||
| 28,500.00 | ||||
| 43,439.76 | ||||
| 24,948.00 | ||||
| 67.200.00 | ||||
| 133,800.00 | ||||
| 45,800.00 | ||||
| 100,980.00 | ||||
| 45,936.00 | ||||
| 55,320.00 | ||||
| 9,240.00 | ||||
| 9,160.00 | ||||
| 18,164.54 | ||||
| 21,687.58 | ||||
| 107,047.98 | ||||
| 37,040.00 | ||||
| 18,200.00 | ||||
| 28,918.96 | ||||
| 90,884.64 | ||||
| 22,659.00 | ||||
| 13,801.40 | ||||
| 68,250.00 | ||||
| 03/03/2021 23 11 13,400 58,692.00 6,075 |
27,033.75 | |||
| 04/03/2021 26 30 16,400 15,830 70,848.00 |
69,335.40 | |||
| 16 05/03/2021 12,799 54,011.78 |
||||
| 9 20 08/03/2021 7,000 29,750.00 16,000 |
68,480.00 | |||
| 7 10,000 8 09/03/2021 2,127 9,082.29 |
43,300.00 | |||
| 13 16,000 5 10/03/2021 3,473 14,899.17 |
69,440.00 | |||
| 11/03/2021 16 12,000 ٠ |
52,560.00 | |||
| 34 12/03/2021 22,095 ۰ ٠ |
98,101.80 | |||
| 32 15/03/2021 22,000 ۰ ٠ |
99,440.00 |
| Buy Side | Sell Side | |||||
|---|---|---|---|---|---|---|
| Number of executions |
Number of shares |
Traded volume in EUR |
Number of executions |
Number of shares |
Traded volume in EUR |
|
| Total | 1,594 | 978,682 | 4.245,529.01 | 1,298 | 906,908 | 3,977,929.37 |
| 16/03/2021 | 18 | 13,395 | 61,081.20 | |||
| 17/03/2021 | 15 | 10,001 | 45,004.50 | 7 | 2,605 | 11,878.80 |
| 18/03/2021 | 16 | 10,047 | 44,910.09 | 8 | 8,000 | 36,240.00 |
| 19/03/2021 | 30 | 20,000 | 88,800.00 | $\overline{a}$ | ||
| 22/03/2021 | 14 | 10,000 | 43,800.00 | - | ٠ | |
| 23/03/2021 | 22 | 14,831 | 64.366.54 | 1 | 1 | 4.42 |
| 24/03/2021 | 16 | 13,570 | 57,672.50 | - | - | |
| 25/03/2021 | 16 | 10,537 | 44.466.14 | ÷ | ||
| 26/03/2021 | ٠ | 1 | 2.000 | 8,520.00 | ||
| 29/03/2021 | 7 | 1,409 | 5,988.25 | 14 | 8.000 | 34,160.00 |
| 30/03/2021 | 18 | 6.001 | 25.264.21 | |||
| 31/03/2021 | 9 | 6.374 | 27,089.50 | |||
| 01/04/2021 | 41 | 27.625 | 119,892.50 | |||
| 06/04/2021 | 13 | 11.000 | 47,960.00 | 11 | 4.000 | 17,920.00 |
| 07/04/2021 | 4 | 3,000 | 13,140.00 | 2 | 51 | 225.42 |
| 08/04/2021 | 8 | 7.019 | 30,673.03 | 4 | 2.401 | 10,588.41 |
| 09/04/2021 | 2 | 1.981 | 8,676.78 | 25 | 13,878 | 61,340.76 |
| 12/04/2021 | 16 | 16,000 | 69,600.00 | ٠ | ||
| 13/04/2021 | 16 | 11,001 | 47,084.28 | 1 | 252 | 1,083.60 |
| 14/04/2021 | 3 | 1,129 | 4,809.54 | 17 | 6.009 | 25,838.70 |
| 15/04/2021 | 21 | 10,000 | 42,600.00 | |||
| 16/04/2021 | 15 | 6,001 | 25,684.28 | 11 | 10,360 | 44,858.80 |
| 19/04/2021 | 11 | 9,927 | 41,891.94 | 1 | 257 | 1,094.82 |
| 20/04/2021 | 12 | 4,000 | 16,640.00 | $\overline{a}$ | ||
| 21/04/2021 | 8 | 4,200 | 17,304.00 | - | ||
| 22/04/2021 | 4 | 2,800 | 11,452.00 | 6 | 4.000 | 16,600.00 |
| 23/04/2021 | 2 | 2,000 | 8,200.00 | 7 | 4,800 | 19,968.00 |
| 26/04/2021 | 21 | 10,322 | 41,804.10 | 3 | 5,100 | 20,910.00 |
| 27/04/2021 | - | 29 | 22,843 | 96,169.03 | ||
| 28/04/2021 | 4 | 4,000 | 16,640.00 | 9 | 6.074 | 25.571.54 |
| 29/04/2021 | 17 | 14.656 | 61,262.08 | 17 | 7.927 | 33,610.48 |
| 30/04/2021 | 22 | 12,071 | 49.973.94 | ٠ | ||
| 03/05/2021 | 9 | 5,322 | 21,979.86 | 6 | 3.405 | 14,130.75 |
| 04/05/2021 | 12 | 7.053 | 29.128.89 | 12 | 8.595 | 35,927.10 |
| 05/05/2021 | 5 | 3,899 | 16,063.88 | 50 | 32,657 | 137,159.40 |
| 06/05/2021 | 24 | 20,000 | 83,600.00 | 1 | 2.000 | 8,520.00 |
| 07/05/2021 | ٠ | 11 | 6,000 | 25,440.00 | ||
| 10/05/2021 | 10 | 8,275 | 34,920.50 | 12 | 10,000 | 42,600.00 |
| 11/05/2021 | 25 | 16,205 | 66,926.65 | |||
| 12/05/2021 | 12 | 6,277 | 26,049.55 | - | ||
| 13/05/2021 | 15 | 8,208 | 33,652.80 | 35 | 26,000 | 108,940.00 |
| 14/05/2021 | 23 | 20,985 | 86,877.90 | 4 | 2,000 | 8,440.00 |
| 17/05/2021 | 11 | 8,564 | 35,369.32 | 5 | 4,000 | 16,640.00 |
| 18/05/2021 | 1 | 1 | 4.18 | 12 | 8,000 | 33,440.00 |
| 19/05/2021 | 21 | 9,999 | 41,595.84 | 16 | 10,000 | 42,100.00 |
| 20/05/2021 | 5 | 3,138 | 13,148.22 | 10 | 8,000 | 33,840.00 |
| 21/05/2021 | 19 | 50,858.22 | 24 | 16,000 | 68,640.00 | |
| 24/05/2021 | 12 | 12,138 | 36,204.60 | |||
| 25/05/2021 | 15 | 8,724 | 14 | 33,596.10 | ||
| 10 | 6,457 | 26,602.84 | 1 | 8,115 | 4.14 | |
| 26/05/2021 | 4,980 | 20,467.80 | 1 | |||
| 27/05/2021 | 9 | 6,000 | 24,660.00 | 17 | 5,736 | 23,689.68 |
| Buy Side | Sell Side | |||||
|---|---|---|---|---|---|---|
| Number of executions |
Number of shares |
Traded volume in EUR |
Number of executions |
Number of shares |
Traded volume in EUR |
|
| Total | 1.594 | 978.682 | 4.245,529.01 | 1,298 | 906.908 | 3,977,929.37 |
| 28/05/2021 | 9 | 4.530 | 18,527.70 | 28 | 26,649 | 110,593.35 |
| 31/05/2021 | 15 | 6,346 | 26.272.44 | 9 | 4.051 | 16,973.69 |
| 01/06/2021 | 2 | 1.443 | 5.974.02 | 27 | 16.218 | 68,277.78 |
| 02/06/2021 | 3 | 6,000 | 25,140.00 | 9 | 4.095 | 17,280.90 |
| 03/06/2021 | 23 | 8.411 | 35.073.87 | 2 | 2.000 | 8,380.00 |
| 04/06/2021 | 28 | 13.800 | 57.132.00 | $\overline{a}$ | ||
| 07/06/2021 | 5 | 4,683 | 19,340.79 | 6 | 2.050 | 8,487.00 |
| 08/06/2021 | 10 | 4.103 | 17,068.48 | 12 | 9.950 | 41.591.00 |
| 09/06/2021 | 21 | 13.214 | 54.441.68 | $\overline{a}$ | ||
| 10/08/2021 | 11 | 6.001 | 24.544.09 | 2 | 696 | 2,874.48 |
| 11/06/2021 | 6 | 4.238 | 17.248.66 | 13 | 4.347 | 17,822.70 |
| 14/06/2021 | 2 | 31 | 127.10 | 25 | 12.390 | 51,170.70 |
| 15/06/2021 | 4 | 2.292 | 9,443.04 | 2 | 975 | 4,046.25 |
| 16/06/2021 | 20 | 7.989 | 32.675.01 | - | ||
| 17/08/2021 | 13 | 5.138 | 20.808.90 | |||
| 18/06/2021 | 17 | 5,443 | 21,826.43 | |||
| 21/06/2021 | 38 | 18,450 | 72.139.50 | |||
| 23/06/2021 | 10 | 7,400 | 28.194.00 | 3 | 2.260 | 8,723.60 |
| 24/06/2021 | 22 | 26.740 | 102.414.20 | |||
| 25/06/2021 | 13 | 8,000 | 30.720.00 | 5 | 2.000 | 7,780.00 |
| 28/06/2021 | 11 | 6.000 | 22.860.00 | $\overline{a}$ | ||
| 29/06/2021 | 2 | 1.000 | 3,770.00 | 3 | 3.698 | 14,089.38 |
| 30/06/2021 | 25 | 6,515 | 24.431.25 |
About Nicox
Nicox S.A. is an international ophthalmology company developing innovative solutions to help maintain vision and improve ocular health. Nicox's lead program in clinical development is NCX 470, a novel nitric oxide-donating prostaglandin analog, for lowering intraocular pressure in patients with glaucoma. The company is also developing NCX 4251, a proprietary formulation of fluticasone, for acute exacerbations of blepharitis. Nicox generates revenue from VYZULTA® in glaucoma, licensed exclusively worldwide to Bausch + Lomb, and ZERVIATE® in allergic conjunctivitis, licensed in multiple geographies, including to Eyevance Pharmaceuticals, LLC, in the U.S. and Ocumension Therapeutics in the Chinese and in the majority of South East Asian markets.
Nicox is headquartered in Sophia Antipolis, France, is listed on Euronext Paris (Compartment B: Mid Caps; Ticker symbol: COX) and is part of the CAC Healthcare, CAC Pharma & Bio and Next 150 indexes.
For more information on Nicox, its products or pipeline, please visit: www.nicox.com.
Analyst coverage
Bryan, Garnier & Co Victor Floc'h Paris, France Cantor Fitzgerald Louise Chen New York, U.S. Edison Investment Research Pooya Hemami London, UK H.C. Wainwright & Co Yi Chen New York, U.S. Kepler Cheuvreux Damien Choplain Paris, France
The views expressed by analysts in their coverage of Nicox are those of the author and do not reflect the views of Nicox. Additionally, the information contained in their reports may not be correct or current. Nicox disavows any obligation to correct or to update the information contained in analyst reports.
Contacts
Nicox
Gavin Spencer Executive Vice President, Chief Business Officer & Head of Corporate Development T +33 (0)4 97 24 53 00 [email protected]
Investors & Media
United States & Europe LifeSci Advisors, LLC Mary-Ann Chang T +44 7483 284 853 [email protected] Media France LifeSci Advisors, LLC Sophie Baumont M +33 (0)6 27 74 74 49 [email protected]
Forward-Looking Statements
The information contained in this document may be modified without prior notice. This information includes forward-looking statements. Such forward-looking statements are not guarantees of future performance. These statements are based on current expectations or beliefs of the management of Nicox S.A. and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Nicox S.A. and its affiliates, directors, officers, employees, advisers or agents, do not undertake, nor do they have any obligation, to provide updates or to revise any forward-looking statements.
Risks factors which are likely to have a material effect on Nicox's business are presented in the 3rd chapter of the 'Document d'enregistrement universel, rapport financier annuel et rapport de gestion 2020' filed with the French Autorité des Marchés Financiers (AMF) on March 1, 2021 which are available on Nicox's website (www.nicox.com).
Nicox S.A. Drakkar 2 Bât D, 2405 route des Dolines CS 10313, Sophia Antipolis 06560 Valbonne, France T +33 (0)4 97 24 53 00 F +33 (0)4 97 24 53 99